Alder BioPharmaceuticals to Host Conference Call to Discuss First Quarter 2017 Financial and Operating Results
April 20 2017 - 8:00AM
Alder BioPharmaceuticals®, Inc. (NASDAQ:ALDR), a clinical-stage
biopharmaceutical company developing monoclonal antibody
therapeutics, today announced that it will report its first
quarter 2017 financial and operating results after the close of
U.S. financial markets on Thursday, April 27, 2017. Alder
management will host a conference call and live audio webcast to
discuss the results and provide a general business update
at 5:00 p.m. ET the same day.
The live call may be accessed by dialing (877) 430-4657 for
domestic callers or (484) 756-4339 for international callers, and
providing conference ID number 94734332. The webcast will be
broadcast live on the investors section of Alder’s website
at www.alderbio.com and will be available for replay following
the call for 30 days.
About Alder
BioPharmaceuticals®
Alder BioPharmaceuticals, Inc., is a clinical-stage
biopharmaceutical company that discovers, develops and seeks to
commercialize genetically engineered therapeutic antibodies with
the potential to meaningfully transform current treatment
paradigms. Alder's lead pivotal-stage product candidate,
eptinezumab, is being evaluated for migraine prevention.
Eptinezumab is a monoclonal antibody that inhibits calcitonin
gene-related peptide (CGRP), a protein that is active in mediating
the initiation of migraine. Alder is additionally evaluating
ALD1910, a preclinical product candidate also in development as a
migraine prevention therapy. ALD1910 is a monoclonal antibody that
inhibits pituitary adenylate cyclase-activating polypeptide-38
(PACAP-38), another protein that is active in mediating the
initiation of migraine. Clazakizumab, Alder's third program, is a
monoclonal antibody candidate that inhibits interleukin-6 and is
licensed to Vitaeris, Inc. For more information, please visit
http://www.alderbio.com.
Media Contacts:
David Schull
Russo Partners, LLC
(212) 845-4271
(646) 942-5627
david.schull@russopartnersllc.com
Investor Relations Contact:
David Walsey
Alder BioPharmaceuticals® Inc.
(425) 408-8032
ir@alderbio.com
Alder BioPharmaceuticals (NASDAQ:ALDR)
Historical Stock Chart
From Apr 2024 to May 2024
Alder BioPharmaceuticals (NASDAQ:ALDR)
Historical Stock Chart
From May 2023 to May 2024